'IM iD'eally treating multiple myeloma.

摘要

The introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors, and other novel agents has dramatically improved the prognosis for patients with MM. However, once patients are no longer responsive to IMiDs and bortezomib, the prognosis is grave and new agents are needed. Pomalidomide is the newest IMiD. Evidence is mounting that suggests at least incomplete cross-resistance among thalidomide, lenalidomide, and pomalidomide, which have very similar chemical structures but differ markedly in their potency and side effects. Their mechanism of resistance to IMiDs is not known but recent studies suggest that a threshold level of cereblon expression is required for response to IMiD therapy.